Cogent Biosciences Inc COGT Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$31.65 up $2.07, 6.98% at close Nov 6
Last close · Previous close $29.58
- Market cap
- $5.41BAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$2.16Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$31.65up $2.07, 6.98%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$29.58Nov 5
- Volume1.48MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume2.17MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $27.74 to $43.73; now $31.65
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
COGT beat the S&P 500 in 4 of 6 periods.
| Period | COGT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | COGT: up 4.2% S&P 500: down 5.6% | COGT beat the S&P 500 by 9.8 percentage points Beat |
| 3M | COGT: down 24.3% S&P 500: down 4.1% | COGT trailed the S&P 500 by 20.2 percentage points Trailed |
| YTD | COGT: down 10.9% S&P 500: up 8.7% | COGT trailed the S&P 500 by 19.6 percentage points Trailed |
| 1Y | COGT: up 115.0% S&P 500: up 10.9% | COGT beat the S&P 500 by 104.1 percentage points Beat |
| Long term | ||
| 3Y | COGT: up 279.0% S&P 500: up 75.0% +55.9% vs +20.5% a year | COGT beat the S&P 500 by 204.0 percentage points Beat |
| 5Y | COGT: up 261.7% S&P 500: up 67.8% +29.3% vs +10.9% a year | COGT beat the S&P 500 by 193.9 percentage points Beat |
$10,000 invested in COGT 5 years ago (Nov 5, 2021) would be worth about $36,166 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
COGT beat the S&P 500 in 4 of 6 periods.
| Period | COGT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | COGT: up 4.2% S&P 500: down 5.6% | COGT beat the S&P 500 by 9.8 percentage points Beat |
| 3M | COGT: down 24.3% S&P 500: down 4.3% | COGT trailed the S&P 500 by 20.0 percentage points Trailed |
| YTD | COGT: down 10.9% S&P 500: up 7.8% | COGT trailed the S&P 500 by 18.7 percentage points Trailed |
| 1Y | COGT: up 115.0% S&P 500: up 9.7% | COGT beat the S&P 500 by 105.3 percentage points Beat |
| Long term | ||
| 3Y | COGT: up 279.0% S&P 500: up 68.8% +55.9% vs +19.1% a year | COGT beat the S&P 500 by 210.2 percentage points Beat |
| 5Y | COGT: up 261.7% S&P 500: up 56.9% +29.3% vs +9.4% a year | COGT beat the S&P 500 by 204.8 percentage points Beat |
$10,000 invested in COGT 5 years ago (Nov 5, 2021) would be worth about $36,166 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$67.08
Closing high on . Now 52.8% below that record.
Split-adjusted daily closes since Mar 29, 2018.
Stock splits
1
1-for-4 on . Share counts adjust after each split.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$2.16 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 10.2×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −5.72%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $4.86BAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own COGT DCF in Excel. Value Cogent Biosciences with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$377.18M
- Diluted EPS
- −$2.16
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$70.63M | −$0.52 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$67.93M | −$0.50 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$71.99M | −$0.52 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$73.53M | −$0.53 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$80.93M | −$0.50 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$102.49M | −$0.61 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$97.35M | −$0.53 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$96.41M | −$0.52 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$72.27M | −$1.87 |
| FY22 (Dec 31, 2022) | $0.00 | −$140.24M | −$1.73 |
| FY23 (Dec 31, 2023) | $0.00 | −$192.41M | −$1.94 |
| FY24 (Dec 31, 2024) | $0.00 | −$255.86M | −$1.94 |
| FY25 (Dec 31, 2025) | $0.00 | −$328.94M | −$2.16 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$309.24MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$307.55MLast 12 months
- Capital spending$1.70MLast 12 months
Shareholder returns
- $722.39MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $792.72MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$244.26MAs of Jun 30, 2026
- Net cash$548.46MAs of Jun 30, 2026
- 13.57As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.46As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −72.6%Last 12 months
Over the last 12 months, Cogent Biosciences lost money: its net loss was 72.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −48.7%Last 12 months
Over the last 12 months, Cogent Biosciences’s net loss was 48.7% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Cogent Biosciences Inc
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2, PI3Kα and KRAS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
COGT news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
COGT stock FAQ
What is COGT stock’s price today?
Cogent Biosciences (COGT) traded at $31.65 at the close on , up $2.07 (6.98%) from the previous close of $29.58. Over the past 52 weeks it has traded between $27.74 and $43.73.
If you invested $1,000 in COGT 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in COGT on would be worth about $3,617 at the close on , a total return of +261.7%. The same $1,000 would be worth $2,150 if invested one year ago. Past performance doesn’t predict future returns.
What is Cogent Biosciences’s market cap?
Cogent Biosciences’s market capitalization is about $5.4 billion. That’s Tiingo’s daily market cap for , at that day’s closing price of $31.65 (how market cap works). Cogent Biosciences reported 170.87M shares outstanding at the end of its latest quarter ().
What is COGT’s P/E ratio?
COGT’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$2.16).
What are COGT’s earnings per share?
COGT’s diluted earnings per share were −$2.16 over the four quarters to , compared with −$2.07 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.52 per share, against −$0.53 a year earlier (how EPS works).
Does COGT pay a dividend?
Cogent Biosciences hasn’t paid a dividend in the last twelve months.
What is COGT’s 52-week high and low?
Over the past 52 weeks COGT has traded as low as $27.74 and as high as $43.73. At $31.65 at the close on , it is 27.6% below that high and 14.1% above the low.
What is COGT’s all-time high?
COGT’s highest closing price was $67.08 on , adjusted for stock splits. At $31.65 at the close on , it is 52.8% below that record.
Has COGT stock ever split?
Yes, once: 1-for-4 on .
How has COGT stock performed?
Including dividends and measured to the close on , COGT has returned −10.9% so far this year and +115.0% over the past year, and +261.7% over five years (+29.3% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Cogent Biosciences in?
Cogent Biosciences is in the Healthcare sector and the Biotechnology industry, and is headquartered in Massachusetts, USA.
What exchange does COGT trade on?
Cogent Biosciences trades on the Nasdaq under the ticker symbol COGT. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.